UF Health Lung Transplant Program Earns Top Marks for Patient Outcomes
UF Health Lung Transplant Program Earns Top Marks for Patient Outcomes
The UF Health lung transplant program has again been recognized by the Scientific Registry of Transplant Recipients, or SRTR, for outstanding patient outcomes, reinforcing its reputation as a premier choice for patients seeking lung transplantation.
The latest SRTR rankings show the program continues to meet or exceed national benchmarks across key measures, including short- and long-term post-transplant survival, waitlist survival and timely access to transplantation.
Updated twice a year, SRTR data provides patients and healthcare professionals with crucial information about transplant center performance. A redesigned interface on the SRTR website makes it easier for patients to review results from their preferred transplant center and compare performance with nearby programs.
“Deciding where to have a lung transplant may well be the most important decision of a patient’s life,” said Mindaugas Rackauskas, M.D., Ph.D., chief of thoracic surgery at the University of Florida College of Medicine and director of the adult and pediatric lung transplant program at UF Health. “We’re glad that patients have easier access to the data, and we’re proud that the data once again reflect UF Health’s status as a premier destination for lung transplantation.”
Amir Emtiazjoo, M.D., M.Sc., section chief and medical director of the lung transplant program, said UF Health’s commitment to patients goes far beyond the operating room.
“Patients place a tremendous amount of trust in us when they choose UF Health,” he said. “We honor that trust by staying with our patients every step of the way, from their first conversations with transplant coordinators to their postoperative recovery. That culture of care is an important part of what makes our center successful.”
Greg Harrison, gregory.harrison@ufl.edu, 570/772-0366
View source version on businesswire.com: https://www.businesswire.com/news/home/20260717064102/en/
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
The 10 Best Companies to Invest in Now
3 Stocks to Sell and 3 Stocks to Buy for October
14 Elite Funds and ETFs, and 5 Popular Funds That Just Missed the Mark
The Top Funds for a Simpler Retirement Portfolio
United States